CytoMed TherapeuticsGDTC
Market Cap: $17.1M
About: CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
Employees: 34
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0% less ownership
Funds ownership: 0% [Q1] → 0% (-0%) [Q2]
100% less funds holding
Funds holding: 1 [Q1] → 0 (-1) [Q2]
100% less capital invested
Capital invested by funds: $28 [Q1] → $0 (-$28) [Q2]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Benchmark Bruce Jackson 27% 1-year accuracy 13 / 48 met price target | 238%upside $5 | Speculative Buy Reiterated | 11 Jun 2024 |